Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1)

Stem Cells and Development

Volumn 19, Issue 5, 2010, Pages 657-668

  Lanz, Tobias V ^a,b   Opitz, Christiane A ^a   Ho, Peggy P ^c   Agrawal, Ankur ^c   Lutz, Christian ^d   Weller, Michael ^e   Mellor, Andrew L ^f   Steinman, Lawrence ^c   Wick, Wolfgang ^a   Platten, Michael ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c STANFORD UNIVERSITY   (United States)

^d Wilex Biotechnology GmbH   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; KYNURENINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRYPTOPHAN; ANTIGEN; MOG PROTEIN, HUMAN; MOG PROTEIN, MOUSE; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CELL MOTILITY; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TARGET CELL; TH1 CELL; TH2 CELL; ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HELPER CELL; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM;

ANIMALS; ANTIGENS; COCULTURE TECHNIQUES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MYELIN PROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 77952895427     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2009.0385     Document Type: Article

References (42)

1. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
2. Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74.
3. Rasmusson I. (2006). Immune modulation by mesenchymal stem cells. Exp Cell Res 312:2169-2179.
4. Zappia E, S Casazza, E Pedemonte, F Benvenuto, I Bonanni, E Gerdoni, D Giunti, A Ceravolo, F Cazzanti, F Frassoni, G Mancardi and A Uccelli. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755-1761.
5. Gerdoni E, B Gallo, S Casazza, S Musio, I Bonanni, E Pedemonte, R Mantegazza, F Frassoni, G Mancardi, R Pedotti and A Uccelli. (2007). Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 61:219-227.
6. Kassis I, N Grigoriadis, B Gowda-Kurkalli, R Mizrachi-Kol, T Ben-Hur, S Slavin, O Abramsky and D Karussis. (2008). Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65:753-761.
7. Mat ysiak M, M Stasiolek, W Orlowski, A Jurewicz, S Janczar, CS Raine and K Selmaj. (2008). Stem cells ameliorate EAE via an indoleamine 2, 3-dioxygenase (IDO) mechanism. J Neuroimmunol 193:12-23.
8. Constantin G, S Marconi, B Rossi, S Angiari, L Calderan, E Anghileri, B Gini, SD Bach, M Martinello, F Bifari, M Galie, E Turano, S Budui, A Sbarbati, M Krampera and B Bonetti. (2009). Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27:2624-2635.
9. Rafei M, PM Campeau, A Aguilar-Mahecha, M Buchanan, P Williams, E Birman, S Yuan, YK Young, MN Boivin, K Forner, M Basik and J Galipeau. (2009). Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 182:5994-6002.
10. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722-3729.
11. Beyth S, Z Borovsky, D Mevorach, M Liebergall, Z Gazit, H Aslan, E Galun and J Rachmilewitz. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105:2214-2219.
12. Jiang XX, Y Zhang, B Liu, SX Zhang, Y Wu, XD Yu and N Mao. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120-4126.
13. Glennie S, I Soeiro, PJ Dyson, EW Lam and F Dazzi. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821-2827.
14. Plumas J, L Chaperot, MJ Richard, JP Molens, JC Bensa and MC Favrot. (2005). Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19:1597-1604.
15. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
16. Meisel R, A Zibert, M Laryea, U Göbel, W Däubener and D Dilloo. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 103:4619-4621.
17. Gieseke F, B Schütt, S Viebahn, E Koscielniak, W Friedrich, R Handgretinger and I Müller. (2007). Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and ID Oexpression. Blood 110:2197-2200.
18. Ryan JM, F Barry, JM Murphy and BP Mahon. (2007). Interferongamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
19. Opitz CA, UM Litzenburger, C Lutz, TV Lanz, I Tritschler, A Köppel, E Tolosa, M Hoberg, J Anderl, WK Aicher, M Weller, W Wick and M Platten. (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27:909-919.
20. Munn DH, E Shaf zadeh, JT Attwood, I Bondarev, A Pashine and AL Mellor. (1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363-1372.
21. Munn DH, M Zhou, JT Attwood, I Bondarev, SJ Conway, B Marshall, C Brown and AL Mellor. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193.
22. Sakurai K, JP Zou, JR Tschetter, JM Ward and GM Shearer. (2002). Effect of indoleamine 2, 3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 129:186-196.
23. Kwidzinski E, J Bunse, O Aktas, D Richter, L Mutlu, F Zipp, R Nitsch and I Bechmann. (2005). Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inf ammation. FASEB J 19:1347-1349.
24. Platten M, PP Ho, S Youssef, P Fontoura, H Garren, EM Hur, R Gupta, LY Lee, BA Kidd, WH Robinson, RA Sobel, ML Selley and L Steinman. (2005). Treatment of autoimmune neuroinf ammation with a synthetic tryptophan metabolite. Science 310:850-855.
25. Opitz CA, W Wick, L Steinman and M Platten. (2007). Try ptophan deg radation in autoim mu ne diseases. Cell Mol Life Sci 64:2542-2563.
26. Baban B, P Chandler, D McCool, B Marshall, DH Munn and AL Mellor. (2004). Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J. Reprod Immunol 61:67-77.
27. Bettelli E, M Pagany, HL Weiner, C Linington, RA Sobel and VK Kuchroo. (2003). Myelin oligodendrocyte glycoproteinspecific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 197:1073-1081.
28. Doucet C, I Ernou, Y Zhang, JR Llense, L Begot, X Holy and JJ Lataillade. (2005). Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cellbased therapy applications. J Cell Physiol 205:228-236.
29. Hervé C, P Beyne, H Jamault and E Delacoux. (1996). Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B, Biomed Appl 675:157-161.
30. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, M Remberger, G Dini, RM Egeler, A Bacigalupo, W Fibbe and O Ringdén; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: a phase II study. Lancet 371:1579-1586.
31. Djouad F, LM Charbonnier, C Bouff, P Louis-Plence, C Bony, F Apparailly, C Cantos, C Jorgensen and D Noël. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25:2025-2032.
32. Ren G, J Su, L Zhang, X Zhao, W Ling, A L'huillie, J Zhang, Y Lu, AI Roberts, W Ji, H Zhang, AB Rabson and Y Shi. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27:1954-1962.
33. Fallarino F, C Vacca, C Orabona, ML Belladonna, R Bianchi, B Marshall, DB Keskin, AL Mellor, MC Fioretti, U Grohmann and P Puccetti. (2002). Functional expression of indoleamine 2, 3-dioxygenase by murine CD8 alpha (+) dendritic cells. Int Immunol 14:65-68.
34. Fujigaki H, K Saito, F Lin, S Fujigaki, K Takahashi, BM Martin, CY Chen, J Masuda, J Kowalak, O Takikawa, M Seishima and SP Markey. (2006). Nitration and inactivation of IDO by peroxynitrite. J Immunol 176:372-379.
35. Pevsner-Fischer M, V Morad, M Cohen-Sfady, L Rousso-Noori, A Zanin-Zhorov, S Cohen, IR Cohen and D Zipori. (2007). Tolllike receptors and their ligands control mesenchymal stem cell functions. Blood 109:1422-1432.
36. Jasperson LK, C Bucher, A Panoskaltsis-Mortari, AL Mellor, DH Munn and BR Blazar. (2009). Inducing the tryptophan catabolic pathway, indoleamine 2, 3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 14: [Epub ahead of print].
37. Braun D, RS Longman and ML Albert. (2005). A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106:2375-2381.
38. Chen W, X Liang, AJ Peterson, DH Munn and BR Blazar. (2008). The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181:5396-5404.
39. Agaugué S, L Perrin-Cocon, F Coutant, P André and V Lotteau. (2006). 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 177:2061-2071.
40. Rafei M, E Birman, K Forner and J Galipeau. (2009). Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther.
41. Steinman L. (2008). A rush to judgment on Th17. J Exp Med 205:1517-1522.
42. Bai L, DP Lennon, V Eaton, K Maier, AI Caplan, SD Miller and RH Miller. (2009). Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia.